Steris Plc Q1 2026 (Ended June 30, 2025) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the first quarter of fiscal year 2026, ended June 30, 2025. Steris Plc is a global provider of infection prevention products and services, operating through three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Dental segment was divested in May 2024 and is reported as discontinued operations. The company is a large accelerated filer incorporated in Ireland.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $1,391.1 million | $1,279.5 million |
| Net Income (Attributable to Shareholders) | $177.4 million | $145.4 million |
| Diluted EPS | $1.79 | $1.46 |
| Operating Income | $246.0 million | $185.5 million |
| Gross Margin | 45.1% | 44.7% |
| Operating Cash Flow | $420.0 million | $303.7 million |
| Free Cash Flow | $326.5 million | $195.7 million |
| Total Debt | $1,903.1 million | $2,043.7 million |
| Cash and Equivalents | $279.7 million | $171.7 million |
| Debt-to-Total Capital | 21.5% | 23.6% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8.7% year-over-year, driven by higher volume and pricing across all segments. Service revenues grew 12.4%, while consumable and capital equipment revenues grew 5.0% and 5.5%, respectively.
- Profitability: Operating income rose 32.6% to $246.0 million. This improvement was primarily due to revenue growth and a significant reduction in restructuring expenses ($1.8 million in Q1 2026 vs. $25.7 million in Q1 2025).
- Restructuring: The company incurred minimal restructuring costs in the current quarter compared to the prior year, as the major costs associated with the May 2024 Restructuring Plan were recognized previously.
- Debt Reduction: Total debt decreased by approximately $140.6 million, largely due to the repayment of $125.0 million in Private Placement Senior Notes.
- Divestitures: The prior year period included a $18.8 million gain on the sale of the Controlled Environment Certification Services (CECS) business, which did not recur in the current period.
Outlook, Risks, and Contingencies
- Guidance: The filing does not contain specific numerical guidance for the full fiscal year 2026. Management expects additional restructuring costs to be insignificant for the remainder of the fiscal year.
- Backlog: Healthcare segment backlog increased to $403.5 million, and Life Sciences backlog rose to $111.0 million, indicating strong order intake.
- Tax Legislation: The U.S. enacted the "One Big Beautiful Bill Act" (OBBBA) on July 4, 2025. The company is assessing the impact of this legislation, which includes changes to international tax rules and cost recovery allowances.
- Legal Contingencies:
- Illinois EO Litigation: The company has entered into settlement agreements to resolve ethylene oxide (EO) exposure claims, with a liability of up to $48.2 million recorded. The claims administration process is expected to continue through Q4 2026.
- IRS Disputes: The company is contesting IRS Notices of Deficiency regarding deemed dividend inclusions, which could result in a cumulative tax liability of approximately $50.0 million. No reserves have been established.
- Share Repurchases: No shares were repurchased under the authorized program in Q1 2026. $300.0 million remains available under the $500.0 million authorization.
Investor Verification Checklist
- Verify the impact of the new U.S. tax legislation (OBBBA) on future effective tax rates.
- Monitor the progress and final cost of the Illinois EO litigation settlement administration.
- Assess the sustainability of the 8.7% revenue growth rate given inflation and tariff cost headwinds mentioned in the MD&A.
- Review the timeline for the recognition of the $1,824.0 million in remaining performance obligations (backlog).
- Confirm the status of the $50.0 million potential IRS tax liability and any updates to the litigation strategy.